Research graph
References from Stratifying Cardiovascular Risk in Patients With <scp>HCC</scp> Receiving Atezolizumab/Bevacizumab: A Comparison of <scp>ESC</scp> and <scp>CARDIOSOR</scp> Scores. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa1915745
10.1056/nejmoa1915745 · External reference
10.1056/evidoa2100070
10.1056/evidoa2100070 · External reference
10.1016/s0140‐6736(25)00403‐9
10.1016/s0140‐6736(25)00403‐9 · External reference
10.1016/j.jhep.2025.03.033
10.1016/j.jhep.2025.03.033 · External reference
10.1016/j.jhep.2021.11.030
10.1016/j.jhep.2021.11.030 · External reference
10.1016/s0140‐6736(23)00961‐3
10.1016/s0140‐6736(23)00961‐3 · External reference
10.1136/gutjnl‐2021‐324915
10.1136/gutjnl‐2021‐324915 · External reference
10.1136/gutjnl‐2020‐322786
10.1136/gutjnl‐2020‐322786 · External reference
10.1016/s2213‐8587(24)00318‐8
10.1016/s2213‐8587(24)00318‐8 · External reference
10.3389/fcvm.2022.988013
10.3389/fcvm.2022.988013 · External reference
10.1016/j.jhep.2021.11.004
10.1016/j.jhep.2021.11.004 · External reference
10.1186/s12874‐021‐01440‐5
10.1186/s12874‐021‐01440‐5 · External reference
10.1111/liv.14941
10.1111/liv.14941 · External reference
2022 ESC Guidelines on Cardio‐Oncology Developed in Collaboration With the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio‐Oncology Society (IC‐OS)
2022 · External reference
10.1161/circulationaha.121.056810
10.1161/circulationaha.121.056810 · External reference
10.1182/blood.2019000840
10.1182/blood.2019000840 · External reference
10.1016/j.ejca.2025.115404
10.1016/j.ejca.2025.115404 · External reference
10.1016/j.jbi.2008.08.010
10.1016/j.jbi.2008.08.010 · External reference
10.1007/s11739‐024‐03578‐8
10.1007/s11739‐024‐03578‐8 · External reference
10.1016/j.annonc.2024.02.005
10.1016/j.annonc.2024.02.005 · External reference
